Expression of the three components of linear ubiquitin assembly complex in breast cancer

Kharman-Biz, Amirhossein; Gao, Hui; Ghiasvand, Reza; Haldosén, Lars-Arne; Zendehdel, Kazem

doi:10.1371/journal.pone.0197183

Cited by 18 publications

(11 citation statements)

References 38 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, previous studies have revealed a markedly negative correlation between RNF31 expression and survival time in a variety of cancer types, such as prostate [ 19 ], breast [ 21 ], gastric [ 16 ], and colon cancers [ 20 ]. In addition, RBCK1 is highly expressed in pulmonary adenocarcinoma [ 23 ], breast cancer [ 24 ], colon cancer [ 25 ], and renal cell carcinoma [ 26 , 27 ]. These observations agree with our findings, suggesting that RNF31 and RBCK1 may be used as prognostic markers in patients with HCC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

RBCK1 promotes hepatocellular carcinoma metastasis and growth by stabilizing RNF31

Chen

Zhao

et al. 2022

Cell Death Discov.

View full text Add to dashboard Cite

RNF31 (HOIP), RBCK1 (HOIL-1L), and SHARPIN are subunits of the linear ubiquitin chain assembly complex. Their function and specific molecular mechanisms in hepatocellular carcinoma (HCC) have not been reported previously. Here, we investigated the role of RNF31 and RBCK1 in HCC. We showed that RNF31 and RBCK1 were overexpressed in HCC and that upregulation of RNF31 and RBCK1 indicated poor clinical outcomes in patients with HCC. RNF31 overexpression was significantly associated with more satellite foci and vascular invasion in patients with HCC. Additionally, RBCK1 expression correlated positively with RNF31 expression in HCC tissues. Functionally, RBCK1 and RNF31 promote the metastasis and growth of HCC cells. Moreover, the RNF31 inhibitor gliotoxin inhibited the malignant behavior of HCC cells. Mechanistically, RBCK1 interacted with RNF31 and repressed its ubiquitination and proteasomal degradation. In summary, the present study revealed an oncogenic role and regulatory relationship between RBCK1 and RNF31 in facilitating proliferation and metastasis in HCC, suggesting that they are potential prognostic markers and therapeutic targets for HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

“…RBCK1 is an RBR E3 ligase [ 22 ]. RBCK1 has been reported to be overexpressed in lung adenocarcinoma [ 23 ], breast cancer [ 24 ], colorectal cancer [ 25 ], and renal cell carcinoma [ 26 , 27 ], where high RBCK1 expression correlates with an unfavorable prognosis. RBCK1 promotes tumor progression through several mechanisms.…”

Section: Introductionmentioning

confidence: 99%

RBCK1 promotes hepatocellular carcinoma metastasis and growth by stabilizing RNF31

Chen

Zhao

et al. 2022

Cell Death Discov.

View full text Add to dashboard Cite

show abstract

“…Ring finger protein 31 (RNF31, also named HOIP), Ran Bp-type and C3HC4-type zinc finger-containing protein 1 (RBCK1), and Ariadne homolog 1 (ARIH1) are members of RBR E3 ligases that are up-regulated in breast cancer [ 18 , 196 , 197 ].…”

Section: Protein Ubiquitinationmentioning

confidence: 99%

“…In the context that histone epigenetic modifications and phosphorylation have been studied intensively in breast cancer [ 42 – 45 ]. However, it has become increasingly clear that other unconventional PTMs, such as acetylation, glycosylation, sumoylation, methylation, ubiquitination, citrullination, and palmitoylation, play equally important effects on the occurrence and progression of breast cancer [ 17 , 18 , 46 – 50 ]. So in this review, we introduce the relationship between these unconventional PTMs and breast cancer from the point of view of their underlying mechanisms in the oncogenesis and cancer progression.…”

Section: Introductionmentioning

confidence: 99%

Unconventional protein post-translational modifications: the helmsmen in breast cancer

et al. 2022

View full text Add to dashboard Cite

Breast cancer is the most prevalent malignant tumor and a leading cause of mortality among females worldwide. The tumorigenesis and progression of breast cancer involve complex pathophysiological processes, which may be mediated by post-translational modifications (PTMs) of proteins, stimulated by various genes and signaling pathways. Studies into PTMs have long been dominated by the investigation of protein phosphorylation and histone epigenetic modifications. However, with great advances in proteomic techniques, several other PTMs, such as acetylation, glycosylation, sumoylation, methylation, ubiquitination, citrullination, and palmitoylation have been confirmed in breast cancer. Nevertheless, the mechanisms, effects, and inhibitors of these unconventional PTMs (particularly, the non-histone modifications other than phosphorylation) received comparatively little attention. Therefore, in this review, we illustrate the functions of these PTMs and highlight their impact on the oncogenesis and progression of breast cancer. Identification of novel potential therapeutic drugs targeting PTMs and development of biological markers for the detection of breast cancer would be significantly valuable for the efficient selection of therapeutic regimens and prediction of disease prognosis in patients with breast cancer.

show abstract

“…Many E3 ubiquitin ligases are known to exhibit abnormal expresseion in tumors, making them valuable diagnostic markers and drug targets 13 . Previous studies have revealed that RBCK1 mRNA level was higher in breast cancer samples as compared with adjacent non-tumor tissues, and the downregulation of RBCK1 was associated with reduced level of estrogen receptor alpha and slow proliferation of breast cancer cells.Thus, RBCK1 may regulate cell cycle progression and proliferation by supporting the transcription of estrogen receptor alpha 14 , 15 . In patients with lung cancer, the high expression of RBCK1 was thought to be associated with adaptive hypoxia 16 .…”

Section: Introductionmentioning

confidence: 99%

RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma

Dai

et al. 2019

Cell Death Dis

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) accounts for approximately 3% of adult malignancies, and the incidence of RCC continues to rise worldwide. Although RCC can be treated with surgery at an early stages, the five-year survival rates have been observed to decline dramatically in patients with advanced disease. Most patients with RCC treated with cytotoxic or targeted drugs will develop resistance at some point during therapy. Thus, it is necessary to identify novel therapeutic targets for RCC. Here, we found that RANBP2-type and C3HC4-type zinc finger-containing 1 (RBCK1) expression was upregulated in human RCC samples. Analysis of multiple public databases revealed the correlation between RBCK1 expression and poor prognosis in RCC patients. Subsequently, we performed RBCK1 depletion experiments in RCC cells that severely affected the in vivo and in vitro proliferation of renal cancer cells. The effects of RBCK1 on cell proliferation could be rescued with p53 expression knockdown in two cell lines expressing wild-type p53. Further experiments demonstrated that RBCK1 could facilitate p53 poly-ubiquitination and degradation by direct interaction with p53. Together, our results show that RBCK1 may serve as a promising target for RCC therapy by restoring p53 functions.

show abstract

Expression of the three components of linear ubiquitin assembly complex in breast cancer

Cited by 18 publications

References 38 publications

RBCK1 promotes hepatocellular carcinoma metastasis and growth by stabilizing RNF31

RBCK1 promotes hepatocellular carcinoma metastasis and growth by stabilizing RNF31

Unconventional protein post-translational modifications: the helmsmen in breast cancer

RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma

Contact Info

Product

Resources

About